Data from - Curated by EPG Health - Last updated 22 March 2018

Accrediting Body

Union of European Medical Specialists (via European Accreditation Council for CME)

Expected length

60 minutes


1 credit



On completion of this activity, you will be able to:

  • Describe the pathophysiology and diagnosis of CLL especially in terms of newer prognostic factors and genetic abnormalities
  • State how currently available treatments and treatment guidelines can be used to manage CLL
  • Define the causes of treatment failure or clinical relapse in patients with CLL
  • Describe the mode of action of newer therapies for CLL
  • State how newer therapies fit into treatment algorithms for CLL

Category Value
Expiry date 28-Jan-18
Credit type Credit
Registration with provider required Yes
Certificate available Yes
Author(s) Prof Dr Stephan Stilgenbauer, MD
Multi session Yes
Intended audience(s) General Practitioner, Specialist, Medical Doctor, Medical Student
Assessment method(s) Multiple choice

Start CME


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content